BTG, Mirada’s cancer treatment planning software nabs CE mark


Interventional medicine player BTG and imaging company Mirada Medical earned a CE mark for their dosimetry software for the planning of selective internal radiation therapy (SIRT) for patients with liver cancer.

The Simplicit90Y software offers digital processing, review and reporting of medical imaging, along with image manipulation and quantification analysis capabilities, according to a statement. These features allow for more standardized and consistent dosimetry planning for Yttrium-90 (90Y) SIRT and for the personalization of each patient’s treatment. The software is intended for nuclear medicine or radiology practitioners to process data from images from planar scans and tomographic scans, according to the statement.

“Dosimetry can be a time intensive and complex process and Simplicity90Y simplifies both dosimetry and post-treatment validation,” said Dr. Etienne Garin, chair professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, in the statement. “Knowing you can use this intuitive software to help deliver a more personalised treatment for each patient, achieving the best dose of 90Y radiation to the tumour while minimising exposure to healthy tissue, gives physicians more confidence.”


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

BTG markets a number of interventional oncology products, including TheraSphere, glass microspheres that deliver a targeted dose of Yttrium-90 to a tumor while minimizing harm to healthy tissue. It also markets the LC Bead Lumi, a radiopaque embolic bead for the embolization of hypervascular tumors, or the disruption of blood flow to such tumors to enable their shrinkage.

BTG teamed up with Philips in February this year to roll out the LC Bead Lumi in the U.S. The device is an upgrade to the LC Bead, which is not visible via imaging.


Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.